Advertisement

Topics

Syros Pharma Presents Data At EHA Supporting Potential Of SY-1425, Its First-In-Class Selective Rara Agonist, In Genomically Defined AML And MDS Patients

20:00 EDT 22 Jun 2017 | BioSpace

Preclinical Data Demonstrate Synergistic Activity of SY-1425 with Standard-of-Care AML and MDS Therapies and Anti-CD38 Therapies, Strengthening Rationale for Ongoing and Future Clinical Investigation of SY-1425 as Both a Monotherapy and Combination Agent Preclinical Data Elucidates Mechanism of...

Original Article: Syros Pharma Presents Data At EHA Supporting Potential Of SY-1425, Its First-In-Class Selective Rara Agonist, In Genomically Defined AML And MDS Patients

NEXT ARTICLE

More From BioPortfolio on "Syros Pharma Presents Data At EHA Supporting Potential Of SY-1425, Its First-In-Class Selective Rara Agonist, In Genomically Defined AML And MDS Patients"

Advertisement
Quick Search
Advertisement
Advertisement